•  
  •  
  •  
  •  

2025-10-06 01:37:58

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Nykaa Quarterly Revenue Update - Q2 FY2026
  • Utkarsh Small Finance Bank Ltd - Q2FY26 Business Update
  • HCL Infosystems Ltd receives final arbitration award in arbitration filed against UIDAI
  • Bank of Baroda - Q2 FY2026 Business Update
  • JTL Industries report highest ever H1 FY26 Volumes at 1,82,210 MT, records 3.5% YoY growth

Keywords Selected:  CADILAHC

Research

  • Quant Pick - Cadila Healthcare - ICICI Direct

Stock Report

  • Zydus receives final approval from USFDA for Vigabatrin Tablets
  • Zydus Cadila receives tentative approval from USFDA for Pimavanserin Capsules
  • Zydus Cadila receives tentative approval from USFDA for Pimavanserin Tablets
  • Zydus receives Orphan Drug Designation from US FDA for ZY-19489, a novel compound to treat malaria
  • Zydus to begin Phase II (a) clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor
  • Zydus Cadila receives tentative approval from USFDA for Cariprazine Capsules
  • Zydus announces EPICS-III™ Phase 2(b)/3 adaptive pivotal clinical trial of Saroglitazar Mg in PBC
  • Cadila Healthcare Ltd enters into an agreement with Enzychem Lifesciences for Covid-19 vaccine
  • Zydus develops new treatment for patients suffering from Chronic Kidney Disease
  • Zydus Cadila receives final approval from USFDA for Decitabine Injection
  • Zydus Cadila gets 180-day exclusivity for Nelarabine injection, announces final approval from USFDA
  • Zydus Cadila receives tentative approval from USFDA for Eluxadoline Tablets
  • Zydus Cadila receives final approval from USFDA for Glycopyrrolate Injection
  • Cadila Healthcare Ltd., to supply 1 crore doses of ZyCoV-D, the world's first Plasmid DNA vaccine to the Government of India
  • Zydus announces 'first patient' randomised in EVIDENCES-X™ Phase II(b) clinical trial of Saroglitazar Mg in NASH
  • Zydus Cadila receives tentative approval from USFDA for Adapalene and Benzoyl Peroxide Gel

Latest Post

  • Nykaa Quarterly Revenue Update - Q2 FY2026
  • Utkarsh Small Finance Bank Ltd - Q2FY26 Business Update
  • HCL Infosystems Ltd receives final arbitration award in arbitration filed against UIDAI
  • Bank of Baroda - Q2 FY2026 Business Update
  • JTL Industries report highest ever H1 FY26 Volumes at 1,82,210 MT, records 3.5% YoY growth


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024